Analysts Expect Heska Corporation (HSKA) to Post $0.39 Earnings Per Share
Wall Street brokerages predict that Heska Corporation (NASDAQ:HSKA) will announce earnings of $0.39 per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Heska Corporation’s earnings. The lowest EPS estimate is $0.38 and the highest is $0.40. Heska Corporation posted earnings per share of $0.45 during the same quarter last year, which indicates a negative year-over-year growth rate of 13.3%. The business is scheduled to announce its next earnings report on Tuesday, November 7th.
On average, analysts expect that Heska Corporation will report full-year earnings of $2.00 per share for the current fiscal year. For the next fiscal year, analysts forecast that the business will post earnings of $2.10 per share, with EPS estimates ranging from $2.00 to $2.25. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Heska Corporation.
Heska Corporation (NASDAQ:HSKA) last announced its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.44 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.07. Heska Corporation had a net margin of 10.70% and a return on equity of 15.87%. The business had revenue of $34.30 million for the quarter, compared to analysts’ expectations of $33.35 million. During the same quarter last year, the firm earned $0.35 EPS. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year.
HSKA has been the topic of several research reports. Aegis initiated coverage on shares of Heska Corporation in a research note on Thursday, June 1st. They set a “buy” rating and a $114.50 price objective on the stock. Benchmark Co. boosted their price objective on shares of Heska Corporation from $106.00 to $120.00 and gave the stock a “buy” rating in a research note on Thursday, August 3rd. BidaskClub lowered shares of Heska Corporation from a “buy” rating to a “hold” rating in a research note on Monday, August 14th. Zacks Investment Research upgraded shares of Heska Corporation from a “hold” rating to a “buy” rating and set a $109.00 target price on the stock in a research note on Friday, August 4th. Finally, B. Riley reiterated a “neutral” rating and issued a $96.50 target price on shares of Heska Corporation in a research note on Thursday, August 3rd. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Heska Corporation presently has an average rating of “Hold” and an average price target of $105.20.
Shares of Heska Corporation (HSKA) traded down 0.13% during trading on Friday, reaching $89.36. 35,859 shares of the company traded hands. The stock has a market capitalization of $645.72 million, a P/E ratio of 45.55 and a beta of 0.91. Heska Corporation has a 12-month low of $46.51 and a 12-month high of $115.00. The firm’s 50 day moving average is $98.08 and its 200-day moving average is $98.84.
WARNING: This piece of content was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/24/analysts-expect-heska-corporation-hska-to-post-0-39-earnings-per-share.html.
In other news, CFO John Mcmahon sold 2,608 shares of the business’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $101.17, for a total transaction of $263,851.36. Following the completion of the transaction, the chief financial officer now directly owns 193 shares of the company’s stock, valued at $19,525.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Nancy Wisnewski sold 825 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $102.21, for a total transaction of $84,323.25. Following the transaction, the executive vice president now directly owns 38,114 shares of the company’s stock, valued at $3,895,631.94. The disclosure for this sale can be found here. 14.70% of the stock is owned by insiders.
A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in Heska Corporation by 31.7% during the second quarter. Vanguard Group Inc. now owns 461,841 shares of the medical research company’s stock valued at $47,141,000 after buying an additional 111,232 shares during the last quarter. Neuberger Berman Group LLC increased its holdings in Heska Corporation by 1.0% during the second quarter. Neuberger Berman Group LLC now owns 449,574 shares of the medical research company’s stock valued at $45,888,000 after buying an additional 4,329 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in Heska Corporation by 18.1% during the second quarter. Russell Investments Group Ltd. now owns 225,388 shares of the medical research company’s stock valued at $23,005,000 after buying an additional 34,594 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Heska Corporation by 29.6% during the first quarter. Bank of New York Mellon Corp now owns 202,552 shares of the medical research company’s stock valued at $21,264,000 after buying an additional 46,231 shares during the last quarter. Finally, State Street Corp increased its holdings in Heska Corporation by 12.7% during the second quarter. State Street Corp now owns 195,970 shares of the medical research company’s stock valued at $19,998,000 after buying an additional 22,053 shares during the last quarter. 81.36% of the stock is owned by institutional investors and hedge funds.
Heska Corporation Company Profile
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related stocks with our FREE daily email newsletter.